Astrocytoma, IDH-Mutant : Understanding Your Pathology Report

Jason Wasserman MD PhD FRCPC
April 24, 2026

Astrocytoma, IDH-mutant, is a type of brain tumor that develops from astrocytes, star-shaped glial cells that support nerve cells throughout the brain and spinal cord. It belongs to a larger group of tumors called diffuse gliomas. Diffuse gliomas are infiltrative, which means the tumor cells spread into the normal brain tissue around them and cannot be fully separated from it — unlike another group of gliomas called circumscribed gliomas (such as pilocytic astrocytoma), which have a clear border and can often be completely removed by surgery. For astrocytoma, IDH-mutant, the infiltrative growth pattern has a major consequence: even when all of the visible tumor is removed during surgery, microscopic tumor cells remain behind in the normal-appearing brain. Surgery is often the first step in treatment. Still, additional therapies — which may include a new targeted drug, radiation, or chemotherapy — are used to control the microscopic tumor that surgery cannot reach.

The term IDH-mutant refers to a tumor with a mutation in one of the IDH genes (IDH1 or IDH2). This is a critically important finding because IDH-mutant astrocytomas behave very differently from tumors without an IDH mutation, such as IDH-wildtype glioblastoma. They grow more slowly, occur in younger patients, respond better to treatment, and are associated with significantly longer survival. The IDH mutation also opens the door to a new kind of targeted therapy that is not available for glioblastoma.

Astrocytoma, IDH-mutant, most often arises in the cerebral hemispheres, particularly the frontal and temporal lobes. Less commonly, it can occur in the parietal or occipital lobes, the brainstem, or the spinal cord. Unlike most other cancers, IDH-mutant astrocytoma can be assigned a World Health Organization (WHO) grade of 2, 3, or 4 based on how the tumor appears under the microscope and certain molecular findings. The grade is one of the most important pieces of information in the pathology report because it guides treatment and predicts how the tumor is likely to behave.

This article will help you understand the findings in your pathology report — what each term means and why it matters for your care.

What are the symptoms of astrocytoma, IDH-mutant?

The symptoms of astrocytoma, IDH-mutant, depend on the tumor’s size, location, and grade. Because many of these tumors grow slowly, especially at lower grades, symptoms often develop gradually over months or even years. Some tumors are discovered incidentally when imaging is performed for another reason, such as after a head injury or for unrelated headaches.

Common symptoms include:

• Seizures — often the first sign of the tumor, particularly for tumors in the cortex. Seizures are especially common in IDH-mutant tumors and are often well-controlled with anti-seizure medication.
• Headaches — sometimes worse in the morning or with activities that increase pressure in the head.
• Weakness or numbness on one side of the body — usually on the opposite side to the tumor.
• Changes in speech, language, or word-finding are common when the tumor is in the left frontal or temporal lobe.
• Vision changes — partial vision loss, double vision, or blurring.
• Changes in thinking, memory, personality, or behavior — especially with frontal lobe tumors. Family members sometimes notice these changes before the patient does.
• Fatigue — can be caused by the tumor itself, by seizures, or by treatment.

What causes astrocytoma, IDH-mutant?

For most people diagnosed with astrocytoma, IDH-mutant, the exact cause is not known. The tumor develops through a series of genetic changes that accumulate in astrocytes over time. The most important of these changes is a mutation in an IDH gene, which disrupts normal cell function and leads to the accumulation of a harmful molecule called 2-hydroxyglutarate inside tumor cells. This molecule changes how genes are turned on and off and helps drive tumor growth.

The only well-established environmental risk factor for astrocytoma is high-dose ionizing radiation to the head, usually from previous cancer treatment. Other factors commonly discussed in the media — including cell phone use, head injuries, and electromagnetic fields — have not been consistently shown to cause brain tumors. The tumor is not contagious and not caused by anything the patient did or did not do.

A small number of astrocytomas develop in the setting of an inherited condition. Inherited conditions are caused by a genetic change that is present in every cell of the body from birth and can be passed from parent to child. Inherited conditions linked to astrocytoma, IDH-mutant, include:

• Li-Fraumeni syndrome — caused by a change in the TP53 gene. This syndrome increases the risk of many cancers, including brain tumors, sarcomas, breast cancer, and leukemia.
• Ollier disease and Maffucci syndrome — conditions characterized by multiple benign cartilage tumors of bone called enchondromas (Ollier disease) and enchondromas plus blood vessel tumors called hemangiomas (Maffucci syndrome). These conditions are associated with IDH mutations and slightly increase the risk of IDH-mutant gliomas, among other cancers.
• Lynch syndrome and constitutional mismatch repair deficiency (CMMRD) — caused by changes in DNA repair genes such as MLH1, MSH2, MSH6, and PMS2. These conditions also increase the risk of colon cancer, endometrial cancer, and several other cancers.
• Turcot syndrome — an older term describing the combination of colon polyps and brain tumors, now recognized as part of familial adenomatous polyposis (APC gene) or Lynch syndrome.

Because most astrocytomas are not associated with an inherited condition, germline (inherited) genetic testing is not routinely recommended. It may be offered when there is a strong family history of related cancers, when a patient is diagnosed at an unusually young age, or when tumor testing suggests a possible inherited change.

How common is astrocytoma, IDH-mutant?

Astrocytoma, IDH-mutant, is uncommon but represents the most common type of diffuse glioma in younger adults. The yearly incidence is approximately 1 case per 100,000 people in North America. The tumor is most often diagnosed between 30 and 45 years of age, with a median age at diagnosis of around 35–40. It is rare in children (where IDH-wildtype tumors are more common) and becomes progressively less common in older adults (where IDH-wildtype glioblastoma predominates). Men and women are affected about equally.

How is the diagnosis made?

The diagnosis of astrocytoma, IDH-mutant, usually begins when brain imaging — most often magnetic resonance imaging (MRI) — reveals a mass. These tumors have several characteristic MRI features that help distinguish them from other brain tumors. They often appear as poorly defined areas of abnormal signal in the frontal or temporal lobes, typically darker than normal brain on T1-weighted images and brighter on T2-weighted images. Lower-grade tumors often show little or no enhancement after intravenous contrast is given, while higher-grade tumors are more likely to enhance and to show swelling or necrosis. A specific imaging finding called the “T2-FLAIR mismatch sign” — where the tumor is very bright on T2 images but relatively dark on FLAIR images — is highly suggestive of astrocytoma, IDH-mutant, especially for grade 2 and 3 tumors.

The diagnosis is confirmed after a tissue sample is examined under the microscope by a pathologist. In most cases, the tissue is obtained during surgery to remove as much of the tumor as can be safely taken out. Surgery serves two purposes: it reduces the amount of tumor in the brain, which improves outcomes and can relieve pressure, and it provides the tissue needed for diagnosis and molecular testing. When the tumor is in a location where surgery would be too risky, a smaller biopsy is performed instead — typically a stereotactic biopsy, in which a thin needle is guided into the tumor using imaging.

Under the microscope, astrocytoma, IDH-mutant, is a diffusely infiltrating tumor, meaning the tumor cells spread into the surrounding brain rather than forming a sharp border. The appearance varies by grade. Grade 2 tumors show a moderate increase in cell number, with enlarged, irregular nuclei and only mild atypia (abnormal appearance); mitotic figures (cells caught in the act of dividing) are rare or absent. Grade 3 tumors are more cellular, show more variation in nuclear shape and size, and have frequent mitotic figures. Grade 4 tumors show features of a high-grade glioma, including necrosis (areas of dead tumor) and microvascular proliferation (abnormal new blood vessel growth).

To confirm that the tumor is glial in origin, the pathologist uses immunohistochemistry, a laboratory test that uses antibodies to detect specific proteins in the tumor cells. Astrocytomas typically express GFAP (glial fibrillary acidic protein) and OLIG2, two proteins that confirm the tumor has arisen from glial cells.

The diagnosis of astrocytoma, IDH-mutant, depends on a combination of microscopic features and molecular findings. A diffuse astrocytic tumor is diagnosed as astrocytoma, IDH-mutant, when molecular testing confirms an IDH1 or IDH2 mutation and when testing for 1p/19q codeletion (the hallmark of oligodendroglioma) is negative. The WHO grade is then assigned based on a combination of microscopic features and specific molecular findings, as described in the next section. Molecular testing is now considered an essential part of the diagnosis and is described in detail in the biomarker section below.

WHO grade

The World Health Organization (WHO) assigns tumors of the central nervous system a grade from 1 to 4 that reflects how the tumor is expected to behave. Astrocytoma, IDH-mutant, is unusual among brain tumors in that it can be assigned a grade of 2, 3, or 4 depending on the tumor’s microscopic appearance and molecular findings. The grade is one of the most important pieces of information in the pathology report because it directly influences treatment decisions and prognosis.

WHO grade 2

Grade 2 tumors grow slowly and, under the microscope, show a moderate increase in cell number, mild nuclear atypia, and few or no mitotic figures. There is no necrosis and no microvascular proliferation. Although grade 2 is sometimes called “low grade,” these tumors should not be considered harmless — nearly all will eventually progress over many years, and treatment is almost always needed. The good news is that patients with grade 2 tumors often live for ten years or more after diagnosis, especially with modern treatment approaches.

WHO grade 3

Grade 3 tumors show more aggressive microscopic features: higher cellularity, more nuclear atypia, and frequent mitotic figures. Necrosis and microvascular proliferation are absent. Grade 3 tumors have an intermediate prognosis, with median survival typically in the range of five to ten years, depending on treatment, age, and other factors.

WHO grade 4

Grade 4 is the highest. A grade 4 diagnosis can be made in two ways. The first is microscopic: the tumor shows necrosis and/or microvascular proliferation, the same features that define a high-grade glioma. The second is molecular: even when the tumor does not show these microscopic features, it is automatically classified as grade 4 if molecular testing reveals homozygous deletion of CDKN2A or CDKN2B (loss of both copies of these tumor suppressor genes). This molecular criterion was added in 2021 because tumors with this change behave aggressively regardless of how the cells look under the microscope. Grade 4 astrocytoma, IDH-mutant, typically has a median survival of about 3 years with modern treatment, which remains significantly longer than that of IDH-wildtype glioblastoma.

Biomarker and molecular testing

Molecular testing is an essential part of the workup for every astrocytoma that is IDH-mutant. The results confirm the diagnosis, distinguish astrocytoma from other diffuse gliomas, assign the WHO grade, determine eligibility for targeted therapy, and identify patients who may benefit from clinical trials.

IDH1 and IDH2

Mutations in the IDH1 and IDH2 genes define astrocytoma, IDH-mutant. These genes normally help cells produce energy; when mutated, they produce an abnormal enzyme that generates a molecule called 2-hydroxyglutarate, which disrupts normal cell function and drives tumor growth. Testing is performed in two steps. The first is an immunohistochemistry stain for the most common IDH1 mutation (R132H); a positive result confirms that the tumor is IDH-mutant. The second is DNA sequencing of IDH1 and IDH2, performed when the immunohistochemistry stain is negative, to detect rarer IDH mutations. IDH mutations are the most important biomarker in this tumor because they define the diagnosis and determine eligibility for the targeted therapy vorasidenib.

1p/19q codeletion

Chromosomes are long DNA strands that contain genes, with a short arm (labeled “p”) and a long arm (labeled “q”). In another type of IDH-mutant diffuse glioma called oligodendroglioma, the short arm of chromosome 1 and the long arm of chromosome 19 are both lost — a change called 1p/19q codeletion. Astrocytoma, IDH-mutant, does not have this change. Testing for 1p/19q codeletion is essential for distinguishing astrocytoma from oligodendroglioma because the two tumors are treated differently. The result is reported as 1p/19q codeleted or 1p/19q intact.

ATRX

The ATRX gene helps maintain the ends of chromosomes, called telomeres. Many astrocytomas, IDH-mutant, have a mutation in ATRX that causes the tumor cells to lose ATRX protein. Immunohistochemistry for ATRX shows loss of staining in tumor cell nuclei, whereas normal cells, such as neurons and blood vessel cells, remain positive and serve as internal controls. Loss of ATRX supports the diagnosis of astrocytoma over oligodendroglioma.

TP53

The TP53 gene is one of the most important tumor suppressor genes in the body. It normally helps damaged cells either repair themselves or die, preventing cancer from forming. Most astrocytomas, IDH-mutant, have a TP53 mutation. This is often detected indirectly by immunohistochemistry, which shows strong, widespread nuclear staining for the p53 protein when the gene is mutated. DNA sequencing can directly confirm the mutation. Like ATRX loss, p53 abnormality supports the diagnosis of astrocytoma over oligodendroglioma.

CDKN2A and CDKN2B

CDKN2A and CDKN2B are tumor suppressor genes that slow cell division. When both copies of CDKN2A and/or CDKN2B are lost — a change called homozygous deletion — tumor cells grow more easily and behave more aggressively. Homozygous deletion of CDKN2A and/or CDKN2B is so important that it automatically upgrades the tumor to WHO grade 4, even if the microscopic features would otherwise suggest a lower grade. Testing is performed using next-generation sequencing with copy-number analysis or fluorescence in situ hybridization (FISH), and the result is reported as intact or homozygously deleted.

Vorasidenib eligibility and other IDH-targeted therapy

The identification of an IDH mutation is not only diagnostic — it also determines eligibility for a targeted therapy called vorasidenib (brand name Voranigo). Vorasidenib is a once-daily pill that blocks the abnormal enzyme produced by mutations in the IDH1 and IDH2 genes, reducing 2-hydroxyglutarate production and slowing tumor growth. In August 2024, vorasidenib received approval from the U.S. Food and Drug Administration for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with an IDH1 or IDH2 mutation, following surgery. Approval was based on the INDIGO clinical trial, which showed that vorasidenib reduced the risk of tumor progression by about 60% compared to placebo and significantly delayed the need for radiation or chemotherapy. Vorasidenib is not currently approved for grade 3 or grade 4 tumors, and it is not approved for patients who have already received radiation or chemotherapy. Vorasidenib is the first major therapeutic advance for IDH-mutant gliomas in more than two decades and represents a meaningful new option for many patients. Approval in Canada and other countries is evolving; ask your treatment team about current access.

Other molecular changes

Comprehensive molecular testing often identifies additional changes that may provide prognostic information or identify targets for clinical trials. Alterations in genes such as CDK4, PDGFRA, MET, MYCN, PIK3CA, PIK3R1, and RB1 are associated with more aggressive behavior in some studies and are generally considered high-risk features. These results do not usually change the primary diagnosis but may influence treatment choices, particularly whether to consider more aggressive therapy or to pursue a clinical trial.

DNA methylation profiling

DNA methylation refers to small chemical tags attached to DNA that help control which genes are turned on or off. Different tumor types have distinct methylation patterns, almost like a fingerprint. DNA methylation profiling compares a tumor’s pattern to a large reference database. It is increasingly used in specialized centers to confirm the diagnosis of astrocytoma, IDH-mutant, to distinguish it from other diffuse gliomas, and to identify tumors with aggressive molecular features. This testing is especially useful when the microscopic findings are ambiguous or when tissue is limited.

For more information about biomarkers and molecular testing across all cancer types, visit the Biomarkers and Genetic Testing section.

What is the prognosis?

Astrocytoma, IDH-mutant, generally has a substantially better prognosis than IDH-wildtype glioblastoma. However,h outcomes vary widely depending on the grade, the patient’s age and overall health, the extent of surgical removal, and the tumor’s molecular features. Typical median survival by grade is:

• WHO grade 2 — more than 10 years, with many patients living 15 years or longer. Almost all tumors eventually progress, but progression may occur slowly over many years.
• WHO grade 3 — approximately 5–10 years, depending on treatment and other factors.
• WHO grade 4 — approximately 3 years on average, which is considerably better than the 15–20 months associated with IDH-wildtype glioblastoma.

Several features influence the outlook:

• Younger age — patients under 40 generally do better than older patients.
• Good overall health and performance status — the ability to carry out normal daily activities at the time of diagnosis — are among the strongest predictors of survival.
• Complete or near-complete surgical removal — patients whose tumors can be largely or entirely removed generally live longer than those whose tumors cannot be safely resected.
• Absence of high-risk molecular features — tumors without CDKN2A/B homozygous deletion or driver gene amplification tend to have better outcomes.
• Lower WHO grade — grade 2 tumors have substantially longer median survival than grade 3 or grade 4 tumors.
• Seizures as the presenting symptom — patients whose tumor is identified because of a seizure (rather than because of progressive neurological symptoms) tend to have better outcomes, likely because their tumors are diagnosed earlier and at a smaller size.

Because treatment has changed substantially in recent years — particularly with the introduction of vorasidenib for grade 2 tumors — older survival figures may underestimate how well many patients do today. Long-term monitoring with repeat imaging is essential, and the plan of care is often revised over time as the tumor evolves.

What happens after the diagnosis?

Astrocytoma, IDH-mutant, is managed by a multidisciplinary team that typically includes a neurosurgeon, a neuro-oncologist, a radiation oncologist, a neuropathologist, and a neuroradiologist. Other members of the team may include a neurologist for seizure management, a neuropsychologist, rehabilitation specialists (physical, occupational, and speech therapy), a social worker, and palliative care, which is often introduced early and alongside active treatment. A geneticist or genetic counselor is involved when an inherited condition is suspected.

Treatment depends on the tumor grade, the patient’s age and overall health, and how much of the tumor can be safely removed during surgery.

Grade 2 tumors

For grade 2 tumors, treatment begins with maximal safe surgical removal. After surgery, the treatment approach depends on whether the tumor is considered high-risk (for example, in patients over 40, or when the tumor could not be fully removed) or lower-risk.

• Vorasidenib — since its approval in August 2024, vorasidenib has become an important option for grade 2 tumors following surgery, particularly for patients who do not yet need radiation or chemotherapy. The drug is a once-daily pill taken for as long as it continues to work, and it has been shown to delay tumor progression and the need for more intensive therapy. Vorasidenib can be especially valuable for younger patients, who often wish to delay radiation as long as possible because of its potential long-term effects on cognitive function.
• Observation — for some patients with small, completely removed tumors, careful observation with regular MRI scans (every 3–6 months) may be appropriate before starting any medical therapy.
• Radiation combined with chemotherapy — for higher-risk grade 2 tumors, or when the tumor grows or progresses, radiation is typically combined with chemotherapy. The two most commonly used chemotherapy regimens are PCV (a combination of procarbazine, lomustine, and vincristine) and temozolomide. Both have been shown to improve survival when added to radiation.

Grade 3 tumors

For grade 3 tumors, treatment typically includes maximal safe surgical removal followed by radiation combined with chemotherapy. Either PCV or temozolomide may be used. The exact regimen depends on the patient’s age, overall health, and other factors, and is selected in discussion with the neuro-oncologist. Vorasidenib is not currently approved for grade 3 tumors, but it is being studied in clinical trials.

Grade 4 tumors

For grade 4 tumors, treatment resembles that for IDH-wildtype glioblastoma, although outcomes are generally better. Treatment typically includes maximal safe surgical removal followed by radiation combined with temozolomide, followed by several cycles of maintenance temozolomide. Tumor-treating fields (Optune) may also be considered. Clinical trial participation is strongly encouraged for patients with grade 4 tumors.

Follow-up and long-term care

Regardless of grade, long-term follow-up is essential. Patients are followed with regular MRI scans to check for tumor growth, with the interval determined by the grade and stability of the tumor. Long-term effects of the tumor and its treatment — on cognitive function, memory, mood, seizure control, hormones, and overall neurological function — are managed by the multidisciplinary team. Neuropsychological testing, rehabilitation therapies, seizure management, and mental health support are important parts of survivorship care. Because astrocytoma, IDH-mutant, often occurs in young adults in the prime of their careers and family life, practical support around work, driving, parenting, and family planning is also an important part of the conversation with the treatment team.

Palliative care focuses on comfort, symptom management, and emotional and spiritual support, and is compatible with ongoing cancer-directed treatment. Early palliative care has been shown to improve quality of life for both patients and families, and is increasingly introduced as a standard part of care rather than only at the end of life.

Questions to ask your doctor

• What is the WHO grade of my tumor — 2, 3, or 4 — and what does the grade mean for my prognosis?
• How much of the tumor was removed during surgery?
• What IDH mutation does my tumor have, and has 1p/19q codeletion testing confirmed this is an astrocytoma rather than an oligodendroglioma?
• Were any high-risk molecular features identified, such as homozygous deletion of CDKN2A or CDKN2B?
• Am I eligible for vorasidenib? If so, when would I start it, and what should I expect?
• Is radiation, chemotherapy, or both part of my initial treatment plan, or can I start with vorasidenib or observation?
• What clinical trials are available for my grade and molecular profile?
• How often will I need MRI scans, and how will we know if the treatment is working?
• What symptoms should I watch for that might indicate the tumor is growing?
• How will seizures be managed, and will I be able to drive?
• What are the expected long-term effects of the tumor and its treatment on cognitive function, memory, and mood?
• What supportive care services are available — neuropsychology, rehabilitation, mental health, and palliative care?
• Should I be referred for genetic counseling or germline genetic testing?
• How can my family and I plan for the road ahead, including work, parenting, and family planning?

For more information about this site, contact us at [email protected].